Literature DB >> 24678355

[Not Available].

Imad Ziouziou1, Tariq Karmouni1, Khalid El Khader1, Abdellatif Koutani1, Ahmed Iben Attya Andaloussi1.   

Abstract

Year:  2014        PMID： 24678355      PMCID： PMC3956835          DOI： 10.5489/cuaj.1608

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  34 in total

Review 1.  Clinical practice. Osteoporosis in men.

Authors:  Peter R Ebeling
Journal:  N Engl J Med       Date:  2008-04-03       Impact factor: 91.245

2.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

3.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  Arch Intern Med       Date:  2006-02-27

4.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

Review 5.  Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Authors:  Sadeka Shahani; Milena Braga-Basaria; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

Review 6.  Androgen deprivation therapy for prostate cancer: new concepts and concerns.

Authors:  Matthew R Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2007-06       Impact factor: 3.243

Review 7.  Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.

Authors:  Tsutomu Nishiyama
Journal:  Urol Oncol       Date:  2013-06-13       Impact factor: 3.498

8.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

Authors:  Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

9.  Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.

Authors:  Patrick E Teloken; Michael Ohebshalom; Najeeb Mohideen; John P Mulhall
Journal:  J Urol       Date:  2007-10-15       Impact factor: 7.450

10.  Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.

Authors:  David P Smith; Madeleine T King; Sam Egger; Martin P Berry; Phillip D Stricker; Paul Cozzi; Jeanette Ward; Dianne L O'Connell; Bruce K Armstrong
Journal:  BMJ       Date:  2009-11-27
View more
  1 in total

1.  Correction in author affilation.

Authors: 
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.